Adcendo
About Adcendo
Adcendo is a Oncology startup based in Copenhagen, Denmark that has raised $75M in venture capital across 1 funding round since 2017. The company reached Series C stage in April 2026 with a $75M round led by Jeito Capital. Adcendo's investor base includes 6 institutional funds, with Jeito Capital leading the most recent equity round.
Adcendo ApS is a Copenhagen-based clinical-stage biotechnology company developing first- and best-in-class antibody-drug conjugate (ADC) therapies for cancers with high unmet medical need. The company was founded as a spin-out from The Finsen Laboratory at Rigshospitalet and the University of Copenhagen, and is currently advancing three ADC candidates in clinical development targeting Tissue Factor, uPARAP, and an undisclosed squamous cell tumor target. Adcendo also maintains operations in Boston, Massachusetts.
Adcendo Funding Rounds Timeline
1 rounds · $75M raised · since 2017
| Round | Date | Amount | Valuation | Lead investor | Co-investors |
|---|---|---|---|---|---|
| Series C | April 2026 | $75M | — | Jeito Capital | Vida Ventures, Bpifrance, EIFO (Export and Investment Fund of Denmark), RA Capital Management, TPG |
Investors in Adcendo
6 institutional investors across 1 rounds
Lead investors
Co-investors
Recent news about Adcendo
Questions about Adcendo
How much has Adcendo raised?
Adcendo has raised $75M across 1 funding round since 2017.
Who are the investors of Adcendo?
Adcendo's investors include Jeito Capital, Vida Ventures, Bpifrance, EIFO (Export and Investment Fund of Denmark), RA Capital Management, TPG.
When was Adcendo's last funding round?
Adcendo's most recent round was a $75M Series C in April 2026, led by Jeito Capital.
Where is Adcendo headquartered?
Adcendo is headquartered in Copenhagen, Denmark, and was founded in 2017 by Niels Behrendt, Lars Engelholm, Christoffer Nielsen, Henrik Stage.